This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial (Quian, JAMA 2023)
The Filtrate looks at a trial that tries to dissect the bumps in creatinine we regularly see with Pip/Tazo. Is it AKI or pseudonephrotoxicity?
The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
Welcome to #TenTweetNephJC tweetorial
— Nephrology Jrnl Club (@NephJC) September 13, 2022
✳️ 10 tweets to catch-up with #NephJC ✳️
Have you ever prescribed piperacillin-tazobactam? Or avoided it due to fear of causing AKI?
Read on to learn more about the ‘nephrotoxin’ versus ‘pseudonephrotoxin’ debate pic.twitter.com/ZKX1ElhZds
